New England Journal of Medicine reports: Alzheimer’s delayed by taking antioxidant vitamin.

Source of new research funding:
Every day a larger percentage of the U.S. population is at risk of getting Alzheimer’s disease because of their age. No one knows what causes Alzheimer’s and there is no known cure. The cause of Alzheimer’s is unknown, although there appears to be a genetic component.

A lot of new government funded research is focused on slowing the destruction of brain cells by the disease. Any delay would enable its suffers to continue to live independently with their memories intact. The U.S. government has stated:

• If the onset of Alzheimer’s were pushed back only five years, it could save the U.S. $50 billion annually.

We don’t care about the government’s motivation. We care that the research work is getting funded and getting done!

NADH is being tested for an Alzheimer’s disease treatment. If someone you know has Alzheimer’s, they have everything to gain and nothing to lose by taking NADH. Now is the time for you to take action. NADH is very safe and can be taken with other medications.

Recent clinical results:
In March 1997, a National Institute on Aging clinical study found:

• taking antioxidants slowed the rate of disability from Alzheimer’s disease.

In May 1997, the New England Journal of Medicine reported:

• The mental deterioration of Alzheimer's can be slowed significantly by taking vitamin E (Vitamin E is a well known antioxidant).
• Researchers want patients in the earlier stages of Alzheimer's. Their hope is that if treatment begins early enough, it might postpone Alzheimer’s disease indefinitely.

NADH was not tested in this antioxidant treatment of Alzheimer's. This study began more than 2 years ago.

This was the first time a study recommending a vitamin treatment was published in the New England Journal of Medicine. For us to provide accurate reporting, we summarize each publication below without any references to NADH.

New England Journal of Medicine report:
A report published in the May 1997 New England Journal of Medicine shows for the first time that the mental deterioration of Alzheimer's can be slowed significantly by two common substances: vitamin E and selegiline. This compound is commonly used to treat Parkinson's disease.

The report went on to say, researchers want to give these substances to patients in earlier stages of Alzheimer's. The hope is that these substances given early enough, might postpone Alzheimer’s disease indefinitely.

National Institute on Aging study:
The two-year study conducted by the National Institute on Aging showed that normal doses of either selegiline - or - high doses of vitamin E, both of which are antioxidants slowed the rate of disability among "moderate to severe" Alzheimer's patients by an average of seven months. Neither substance reversed the disease.

Dr. Mary Sano, Neuropsychologist, Columbia University in NYC, who led the National Institute on Aging study, states:

• For those Alzheimer’s patients who took either selegiline - or - high doses of vitamin E, the effects were dramatic. They were able to maintain daily functions, such as dressing themselves and handling money. They stayed out of institutions several months longer than patients with the same severity of symptoms who did not take either substance.

Dr. Sano, wants to go on record saying::

• This delaying of Alzheimer’s is very important. These outcomes are directly related to the quality of life for both the patients and their families.

Time Magazine:
You can read a summary of the National Institute on Aging study in Time Magazine May 5, 1997 Vol. 149 No. 18.

Alzheimer's NADH Treatment Clinical Study
In a open label trial of Alzheimer's patients, NADH was used as the medication in the treatment of Alzheimer's disease. The patients received NADH by oral tablets. You can get the same NADH oral tablet here at this web site. The NADH oral tablet is called Co-E1®.

We have included the Alzheimer's disease clinical trial results in this web site. It is very difficult to read, and very technical in nature. The clinical trial study results are usually read by health care professionals. The section is for the people who want to bring the actual clinical research study to their doctor or health care professional.

. . . Alzheimer's disease & Depression
starts on the next page